Tirbanibulin for Pediatric Warts
ConditionWarts Hand
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age8-18
SponsorThe Skin Center Dermatology Group
About this trial
Warts are common, benign skin lesions caused by the human papillomavirus (HPV). Treatment is challenging, particularly in the pediatric population, where standard modalities such as cryotherapy and intralesional immunotherapy are poorly tolerated. Existing topical treatments, such as imiquimod and 5-fluorouracil, have low efficacy and require prolonged use. Case reports suggest tirbanibulin ointment may provide an effective and well-tolerated alternative for pediatric warts. This study will evaluate the efficacy and safety of tirbanibulin ointment in treating pediatric hand warts.
Eligibility criteria
Qualifiers
Age 8-18
Subject and their legally authorized representative must be able to understand and be willing to adhere to all protocol requirements and voluntarily sign and date informed consent and assent for minors.
Subject is judged to be in good health as determined by the Principal Investigator, based upon the results of the screening assessments and medical history.
Diagnosis of warts on the hands
Disqualifiers
Wart duration >2 years.
More than 10 warts in non-hand areas.
Total wart surface area on the hands bigger than 100 cm2
Trial design
Treatments tested in this trial
- Tirbanibulin ointment 1%
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov